DOCMORRIS N news, videos and press releases
For more news please use our advanced search feature.
DOCMORRIS N - More news...
DOCMORRIS N - More news...
- DocMorris AG: DocMorris demands fully digital non-discriminatory access to e-prescriptions
- DocMorris announces results of tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
- DocMorris (formerly Zur Rose Group) announces a tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
- New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)
- Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)
- Zur Rose Group has successfully completed the sale of its Swiss business to Migros
- Zur Rose Group: Revenue in the first quarter 2023 in line with plan
- Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023
- Zur Rose Group: Revenue and earnings targets for 2022 achieved; significant step towards profitability
- Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany
- Zur Rose Group: Revenue target 2022 achieved, EBITDA better than expected
- Zur Rose Group takes next step towards profitability and further reduces complexity in Germany
- Procurement and supply chain brought together under the new Chief Operations Officer
- Zur Rose Group announces results of Tender Offer
- After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022
- Zur Rose Group announces preliminary result and extension of Tender Offer
- Zur Rose Group announces a tender offer for all of its CHF 115 million outstanding bonds due 2023
- Final allocations of Zur Rose approx. CHF 95 million Convertible Bonds Offering
- Zur Rose Group successfully completes placement of approx. CHF 95 million Convertible Bonds and the approx. CHF 44 million Capital Increase by way of an accelerated book building process
- Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. CHF 50 million Capital Increase by way of an accelerated book building process
- Zur Rose Group speeds up path to profitability and plans break-even at EBITDA level in 2023
- Betül Susamis Unaran leaves Zur Rose Group
- Zur Rose Group AG: Shareholders approve all proposals
- Zur Rose Group sees revenue perform as expected in the first quarter of 2022
- Zur Rose Group AG publishes invitation to the Annual General Meeting of 28 April 2022
- Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued
- EQS-News: Zur Rose Group: steady growth in a volatile market environment
- EQS-News: Zur Rose Group nominates Rongrong Hu as director
- EQS-Adhoc: Zur Rose Group successfully completed capital increase from authorised capital and sets placement price at CHF 290 per new share
- EQS-Adhoc: Zur Rose Group decides on capital increase from authorised capital and starts accelerated bookbuilding to make full use of increasing market opportunities
